Target Price | €42.98 |
Price | €41.28 |
Potential | 4.14% |
Number of Estimates | 18 |
18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €42.98. This is 4.14% higher than the current stock price. The highest price target is €49.49 19.91% , the lowest is €38.95 5.63% . | |
A rating was issued by 24 analysts: 14 Analysts recommend Qiagen to buy, 10 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 4.14% . Most analysts recommend the Qiagen stock at Purchase. |
27 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 6.36% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 11.28% , the lowest is €1.7b 0.63% .
This results in the following potential growth metrics:
2024 | €1.7b | 0.66% |
---|---|---|
2025 | €1.8b | 6.36% |
2026 | €1.9b | 5.70% |
2027 | €2.0b | 6.79% |
2028 | €2.3b | 12.76% |
2029 | €2.5b | 9.82% |
2030 | €2.9b | 14.08% |
24 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €679m . This is 57.34% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €773m 78.59% , the lowest is €586m 35.56% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €433m | 10.64% |
---|---|---|
2025 | €679m | 57.34% |
2026 | €732m | 7.74% |
2027 | €795m | 8.69% |
2028 | €852m | 7.14% |
2029 | €910m | 6.83% |
2024 | 25.51% | 9.92% |
---|---|---|
2025 | 37.73% | 47.93% |
2026 | 38.46% | 1.93% |
2027 | 39.14% | 1.77% |
2028 | 37.19% | 4.98% |
2029 | 36.18% | 2.72% |
27 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €443m . This is 519.30% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €461m 542.78% , the lowest is €422m 489.06% .
This results in the following potential growth metrics and future Net Margins:
2024 | €71.7m | 75.51% |
---|---|---|
2025 | €443m | 519.30% |
2026 | €481m | 8.61% |
2027 | €528m | 9.69% |
2028 | €592m | 12.17% |
2029 | €631m | 6.55% |
2024 | 4.23% | 75.67% |
---|---|---|
2025 | 24.60% | 482.19% |
2026 | 25.28% | 2.76% |
2027 | 25.97% | 2.73% |
2028 | 25.83% | 0.54% |
2029 | 25.06% | 2.98% |
27 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.05 . This is 561.29% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.13 587.10% , the lowest is €1.95 529.03% .
This results in the following potential growth metrics and future valuations:
2024 | €0.33 | 74.81% |
---|---|---|
2025 | €2.05 | 521.21% |
2026 | €2.23 | 8.78% |
2027 | €2.44 | 9.42% |
2028 | €2.74 | 12.30% |
2029 | €2.92 | 6.57% |
Current | 131.90 | 1.95% |
---|---|---|
2025 | 19.95 | 84.88% |
2026 | 18.37 | 7.92% |
2027 | 16.75 | 8.82% |
2028 | 14.93 | 10.87% |
2029 | 14.02 | 6.10% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 5.07 and an P/S ratio of 4.95 .
This results in the following potential growth metrics and future valuations:
Current | 5.39 | 2.86% |
---|---|---|
2025 | 5.07 | 5.99% |
2026 | 4.79 | 5.40% |
2027 | 4.49 | 6.36% |
2028 | 3.98 | 11.31% |
2029 | 3.63 | 8.94% |
2030 | 3.18 | 12.34% |
Current | 5.27 | 5.98% |
---|---|---|
2025 | 4.95 | 5.98% |
2026 | 4.69 | 5.40% |
2027 | 4.39 | 6.36% |
2028 | 3.89 | 11.32% |
2029 | 3.54 | 8.94% |
2030 | 3.11 | 12.34% |
Analyst | Rating | Action | Date |
---|---|---|---|
B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Feb 07 2025 |
Morgan Stanley |
Overweight
➜
Equal-Weight
|
Downgrade | Jan 06 2025 |
Analyst Rating | Date |
---|---|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Feb 07 2025 |
Downgrade
Morgan Stanley:
Overweight
➜
Equal-Weight
|
Jan 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.